45/120
1.9 / 5 stars
All 120 Win/Lose results shown below
BIO Roast Me summary
BIO-RAD LABORATORIES, INC. (BIO). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBIO / S&P 5.33% / 15.20% |
LoseBIO / S&P 1.37% / 15.00% |
LoseBIO / S&P -32.46% / 50.40% |
| 2026-Q10/3 |
LoseBIO / S&P -8.00% / -4.33% |
LoseBIO / S&P 1.92% / 11.30% |
LoseBIO / S&P BIO unavailable / 27.70% |
| 2025-Q41/3 |
WinBIO / S&P 8.06% / 2.65% |
LoseBIO / S&P 0.65% / 9.00% |
LoseBIO / S&P BIO unavailable / 13.40% |
| 2025-Q31/3 |
WinBIO / S&P 16.19% / 8.12% |
LoseBIO / S&P -0.88% / 4.61% |
LoseBIO / S&P BIO unavailable / 13.45% |
| 2025-Q20/3 |
LoseBIO / S&P -0.92% / 10.94% |
LoseBIO / S&P -0.33% / 4.83% |
LoseBIO / S&P BIO unavailable / 10.63% |
| 2025-Q10/3 |
LoseBIO / S&P -25.86% / -4.27% |
LoseBIO / S&P -2.46% / 4.98% |
LoseBIO / S&P BIO unavailable / 10.57% |
| 2024-Q40/3 |
LoseBIO / S&P -1.81% / 2.41% |
LoseBIO / S&P -3.92% / 5.25% |
LoseBIO / S&P BIO unavailable / 6.15% |
| 2024-Q31/3 |
WinBIO / S&P 22.51% / 5.89% |
LoseBIO / S&P -5.15% / 5.89% |
LoseBIO / S&P BIO unavailable / 6.11% |
| 2024-Q20/3 |
LoseBIO / S&P -21.04% / 4.28% |
LoseBIO / S&P -7.46% / 5.38% |
LoseBIO / S&P BIO unavailable / 5.12% |
| 2024-Q10/3 |
LoseBIO / S&P 7.12% / 10.56% |
LoseBIO / S&P -6.26% / 5.71% |
LoseBIO / S&P BIO unavailable / 5.59% |
| 2023-Q40/3 |
LoseBIO / S&P -9.92% / 11.69% |
LoseBIO / S&P -4.67% / 6.81% |
LoseBIO / S&P BIO unavailable / 7.78% |
| 2023-Q30/3 |
LoseBIO / S&P -5.45% / -3.27% |
LoseBIO / S&P -3.01% / 7.52% |
LoseBIO / S&P BIO unavailable / -5.03% |
| 2023-Q20/3 |
LoseBIO / S&P -20.86% / 8.74% |
LoseBIO / S&P -3.55% / 9.50% |
LoseBIO / S&P BIO unavailable / -8.57% |
| 2023-Q11/3 |
WinBIO / S&P 13.92% / 7.50% |
LoseBIO / S&P -4.03% / 10.77% |
LoseBIO / S&P BIO unavailable / -15.69% |
| 2022-Q40/3 |
LoseBIO / S&P 0.80% / 7.56% |
LoseBIO / S&P -4.12% / 11.88% |
LoseBIO / S&P -186.48% / -17.99% |
| 2022-Q30/3 |
LoseBIO / S&P -15.73% / -4.88% |
LoseBIO / S&P -5.87% / 13.47% |
LoseBIO / S&P -191.10% / -1.41% |
| 2022-Q21/3 |
WinBIO / S&P -12.11% / -16.10% |
LoseBIO / S&P -0.31% / 13.71% |
LoseBIO / S&P -148.82% / 11.04% |
| 2022-Q10/3 |
LoseBIO / S&P -25.46% / -4.60% |
LoseBIO / S&P 7.22% / 15.97% |
LoseBIO / S&P -103.05% / 42.23% |
| 2021-Q40/3 |
LoseBIO / S&P 1.29% / 11.03% |
LoseBIO / S&P 14.81% / 15.00% |
LoseBIO / S&P 11.35% / 96.40% |
| 2021-Q33/3 |
WinBIO / S&P 15.78% / 0.58% |
WinBIO / S&P 25.18% / 10.77% |
WinBIO / S&P 88.91% / 69.42% |
| 2021-Q23/3 |
WinBIO / S&P 12.80% / 8.55% |
WinBIO / S&P 25.56% / 6.58% |
WinBIO / S&P 108.33% / 51.81% |
| 2021-Q12/3 |
LoseBIO / S&P -2.02% / 6.17% |
WinBIO / S&P 15.94% / -1.06% |
WinBIO / S&P 160.88% / 7.39% |
| 2020-Q43/3 |
WinBIO / S&P 13.09% / 12.15% |
WinBIO / S&P 10.12% / -3.72% |
WinBIO / S&P 117.04% / -33.42% |
| 2020-Q33/3 |
WinBIO / S&P 14.17% / 8.93% |
WinBIO / S&P 3.31% / -2.04% |
WinBIO / S&P 832.99% / -27.10% |
| 2020-Q23/3 |
WinBIO / S&P 28.79% / 20.54% |
WinBIO / S&P 0.22% / -0.46% |
WinBIO / S&P 114.32% / -27.11% |
| 2020-Q12/3 |
WinBIO / S&P -5.26% / -19.60% |
LoseBIO / S&P 1.64% / 3.47% |
WinBIO / S&P 173.30% / -14.75% |
| 2019-Q42/3 |
WinBIO / S&P 11.21% / 9.07% |
LoseBIO / S&P 0.97% / 5.36% |
WinBIO / S&P 381.57% / 2.99% |
| 2019-Q31/3 |
WinBIO / S&P 6.45% / 1.70% |
LoseBIO / S&P 0.44% / 5.02% |
LoseBIO / S&P -70.39% / 0.21% |
| 2019-Q20/3 |
LoseBIO / S&P 2.26% / 4.30% |
LoseBIO / S&P 0.25% / 6.64% |
LoseBIO / S&P -11.81% / 8.65% |
| 2019-Q11/3 |
WinBIO / S&P 31.63% / 13.65% |
LoseBIO / S&P 3.63% / 8.12% |
LoseBIO / S&P -24.86% / 14.29% |
| 2018-Q41/3 |
LoseBIO / S&P -25.81% / -13.52% |
LoseBIO / S&P 5.98% / 9.05% |
WinBIO / S&P 197.30% / 18.23% |
| 2018-Q32/3 |
WinBIO / S&P 8.47% / 7.71% |
LoseBIO / S&P 8.70% / 10.21% |
WinBIO / S&P 7729.63% / 19.06% |
| 2018-Q23/3 |
WinBIO / S&P 15.38% / 3.43% |
WinBIO / S&P 9.50% / 9.03% |
WinBIO / S&P 7834.88% / 14.46% |
| 2018-Q12/3 |
WinBIO / S&P 4.78% / -0.76% |
LoseBIO / S&P 5.47% / 7.68% |
WinBIO / S&P 2821.84% / 12.46% |
| 2017-Q42/3 |
WinBIO / S&P 7.40% / 6.64% |
LoseBIO / S&P 4.45% / 7.03% |
WinBIO / S&P 362.50% / 13.82% |
| 2017-Q30/3 |
LoseBIO / S&P -1.81% / 4.48% |
LoseBIO / S&P 2.08% / 5.68% |
LoseBIO / S&P -83.07% / 17.57% |
| 2017-Q21/3 |
WinBIO / S&P 13.53% / 3.09% |
LoseBIO / S&P 2.78% / 4.83% |
LoseBIO / S&P -86.39% / 17.74% |
| 2017-Q12/3 |
WinBIO / S&P 9.36% / 6.07% |
WinBIO / S&P 3.93% / 3.67% |
LoseBIO / S&P -75.28% / 13.32% |
| 2016-Q42/3 |
WinBIO / S&P 11.28% / 3.82% |
WinBIO / S&P 2.41% / 2.09% |
LoseBIO / S&P -76.28% / 7.05% |
| 2016-Q32/3 |
WinBIO / S&P 14.54% / 3.85% |
WinBIO / S&P 0.99% / 0.20% |
LoseBIO / S&P -9.12% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 30.28% | 20.78% |
| Annualized return | 30.28% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -52.38% | 83.14% |
| Annualized return | -13.79% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 159.60% | 319.30% |
| Annualized return | 10.01% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.